Axcella Health — Technical Presentation (August 2022)
51 slides from Axcella Health's technical presentation, Aug 2, 2022
Slide 1: Phase 2A Long COVID Study Results Presentation
© 2022 Axcella Therapeutics. All rights reserved. NASDAQ: AXLA Axcella Therapeutics Phase 2A Long COVID Study Results Presentation Bill Hinshaw , President and CEO, Axcella August 2022
Slide 2: Forward-Looking Statements
© 2022 Axcella Therapeutics. All rights reserved. 2 Forward - Looking Statements This presentation contains forward - looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 , as amended, including, without limitation, statements regarding the characteristics, c
Slide 3: Today's Agenda
*** Confidential *** © 2022 Axcella Therapeutics. All rights reserved. Today’s Agenda Agenda Length Time Speaker Introductory Remarks 5 min 8:00 am – 8:05 am Bill Hinshaw Clinical Trial Design and Protocol 10 min 8:05 am – 8:15 am Dr . Raman Clinical Trial Results 20 min 8:15 am – 8:35 am Margaret K
Slide 4: World leader of multi-targeted therapies in complex diseases
© 2022 Axcella Therapeutics. All rights reserved. 4 World leader of multi - targeted therapies in complex diseases Endogenous Metabolic Modulators (EMMs) AXA1125 Long COVID
Slide 5: Long COVID prevalence and references
© 2022 Axcella Therapeutics. All rights reserved. 5 1. WHO Coronavirus (COVID - 19) Dashboard: https://covid19.who.int/ 2. American Academy of Physical Medicine and Rehabilitation’s “PASC Dashboard”. PASC = Post - acute Sequelae of COVID - 19. https://pascdashboard.aapmr.org/ 3. Science & Tech Spotl
Slide 6: Very Limited Development and Axcella Leadership Opportunity
© 2022 Axcella Therapeutics. All rights reserved. 6 Very Limited Development and Axcella Leadership Opportunity Very Few Trials in Long COVID and almost none in Fatigue And Growing Attention to this Public Health Crisis Axcella Leadership Opportunity • Differentiated Profile • Most Advanced Program
Slide 7: Long COVID Overview
*** Confidential *** © 2022 Axcella Therapeutics. All rights reserved. Long COVID Overview Betty Raman British Heart Foundation Oxford Centre for Research Excellence Intermediate Transition Clinical Review Fellow Associate Professor of Cardiovascular Medicine Radcliffe Department of Medicine Univers
Slide 8: Long COVID/Post-Acute Sequelae of COVID
Long COVID/Post - Acute Sequelae of COVID - 19 Betty Raman MBBS FRACP DPhil Associate Professor of Cardiovascular Medicine Radcliffe Department of Medicine University of Oxford, United Kingdom British Heart Foundation Oxford Centre of Research Excellence Transition Intermediate Research Fellow NIHR
Slide 9: Long COVID Overview
9 © 2021 Axcella Therapeutics. All rights reserved. Long COVID Overview Betty Raman British Heart Foundation Oxford Centre for Research Excellence Intermediate Transition Clinical Research Fellow Associate Professor of Cardiovascular Medicine Radcliffe Department of Medicine University of Oxford
Slide 10: Long COVID: UK Prevalence June to July, 2022
Long COVID: UK Prevalence 2 1 June to 7 July, 2022 7 July 2022 7 July 2022 56% 31% 22% 21% Loss of smell Loss of smell Muscle ache Source: https:// www.ons.gov.uk /
Slide 11: Long COVID: Patient Journey
• “I have lost everything – my job, my life, my partner. Most of all I have lost myself. I want the old me back.” – P.L Long COVID: Patient Journey Source:https :// www.youtube.com / watch?v =IIeOoS_A4c8 Long COVID SOS support
Slide 12: Post-viral fatigue syndrome and myalgic encephalitis
Post - viral fatigue syndrome and myalgic encephalitis • 1918 Spanish influenza • 2003 SARS • 2009 H1N1 • Ebola virus • Ebstein Barr Virus • Human Herpes Virus CFS No approved treatment for Long COVID or related disorders…..
Slide 13: Long COVID: Research in Oxford
Long COVID: Research in Oxford • C - MORE study – holistic multisystem study (Raman & Neubauer) • Urgent Public Health Badging, NIHR - BHF COVID - 19 Flagship status • Impact on individuals • 3 UK National post - COVID - 19 studies – PHOSP - COVID, CONVALESCENCE, EXPLAIN study Raman B et al, EClinic
Slide 14: Long COVID: Insights from Oxford
Long COVID: Insights from Oxford • Fatigue – most challenging and debilitating symptom experienced by patients • Mitochondrial dysfunction highly likely – insights from CPET Preserved breathing reserve Normal O2 pulse Normal cardiac function and volume Early Anaerobic threshold 3 Cassar . M et al, E
Slide 15: Mitochondrial dysfunction – COVID-SARS-CoV
Mitochondrial dysfunction – COVID - 19 SARS - CoV - 2 Direct effects Inhibit mitochondrial anti - viral signaling proteins (MAVS) 1 Increased ROS 1,2,3 Activation of inflammasomes inflammation 1,2 Muted interferon signaling Release of mitokines 1 Indirect effects ACE2 – activation of RAA 1 Chronic i
Slide 16: Potential mechanisms underlying Long COVID
Potential mechanisms underlying Long COVID Y Interleukins 2 , chemokines Mitochondrial dysfunction 3 T and B cells 1. Raman B et al, European Heart Journal, 2022 2. Evans et al, Lancet Respiratory Medicine, 2022 3. Singh et al, Chest, 2022 4. Richter et al, Clin and Exper Immun , 2022 5. Pretorius e
Slide 17: Clinically Meaningful Measures for Regulators, Treaters, and Patients
Clinically Meaningful Measures are Most Meaningful to Regulatory Agencies, Treaters, and Patients Clinically Meaningful Markers of Efficacy Proof of Hypothesized Mitochondrial Mechanism • Phosphocreatine Recovery Time ( PCr , primary endpoint): measure of mitochondrial oxidative capacity • Other mea
Slide 18: Chalder Fatigue Questionnaire
Chalder Fatigue Questionnaire Do you have problems with tiredness? Do you need to rest more? Do you feel sleepy or drowsy? Do you have problems starting things? Do you lack energy? Do you have less strength in your muscles? Do you feel weak? Do you have difficulty concentrating? Do you make slips of
Slide 19: Phosphocreatine and mitochondrial metabolism
PCr ADP ATP Mitochondrial metabolism ATPase • Phosphocreatine ( PCr ) 1 • Anaerobic metabolism (glycolytic) • Aerobic metabolism Glycogen Mitochondria Sarcomere Lactic acid ATP Recovery α oxidative metabolism 1. Chance et al,PNAS , 1981 PCr = Phosphocreatine
Slide 20: PCr recovery time constant
• Normal recovery time constant 27 ± 7 sec 1 ; 31 ± 7sec 2 ; 32 ± 3sec 3 • > 50s is prolonged (>2SD of published norms) • CFS studies – MRS abnormalities in fatigued patients 4 PCr recovery time constant ϭ͘ zŽƐŚŝĚĂĞƚĂů͕ ^ĐĂŶĚ :DĞĚ^Đŝ^ƉŽƌƚƐ͕͘ ϮϬϭϯ Ϯ͘ aĞĚŝǀ LJ ǵ ĞƚĂů͕DĞĚWŚLJƐ͕ ϮϬϭϱ ϯ͘ ^ĐŚĞƵĞƌŵĂŶŶ Ͳ &ƌĞĞ
Slide 21: Clinical Trial Study Design
Clinical Trial Study Design Screening 1:1 Randomization (N=~40) AXA1125 33.9g BID (67.8 g/d) (n=~20) Matched placebo (n=~20) Follow - up 4 weeks ZHHN D1: 6 - minute walk Lactate Fatigue PRO D28: MRS 6 - minute walk Lactate Fatigue PRO D14: Fatigue PRO Core elements Description Design • Randomized do
Slide 22: AXA1125 - Top Line Data
© 2022 Axcella Therapeutics. All rights reserved. NASDAQ: AXLA *** Confidential *** AXA1125 - 201 Top Line Data Dr. Margaret Koziel 2 August 2022
Slide 23: Executive Summary
© 2022 Axcella Therapeutics. All rights reserved. 23 CFQ - 11, Chalder Fatigue Questionnaire 11 item scale; PCr t , phosphocreatine recovery rate time constant Executive Summary • AXA1125, compared to placebo, resulted in – Statistically significant improvements in fatigue as measured by CFQ - 11 –
Slide 24: AXA1125-201: Demographics
© 2022 Axcella Therapeutics. All rights reserved. 24 *Based on calculated norm for age, gender, BMI; SD, standard error AXA1125 - 201: Demographics All subjects completed all key assessments in the trial Demographics Placebo (n=20) AXA1125 (n=21) Age, mean, years (SD) 43.6 (7.8) 43.6 (10.1) Sex (% f
Slide 25: Statistically Significant Change in Fatigue Scores
© 2022 Axcella Therapeutics. All rights reserved. 25 p - values from ANCOVA and represent LSM adjusting for differences in baseline There is a Statistically Significant Change in Fatigue Scores Improvements seen in all scores using Likert scoring of CFQ - 11 28.05 26.45 26.24 21 0 5 10 15 20 25 30 B
Slide 26: Greater Movement from Moderate/Severe to Mild in Physical & Mental Scales
© 2022 Axcella Therapeutics. All rights reserved. 26 Physical scale: Normal, 0 - 9; Mild, 10 - 15; Moderate severe, ≥16 Mental scale: Normal, 0 - 3; Mild, 4 - 7; Moderate/severe, ≥8 Note denominator based on total in arm for percent Visit Baseline Category Post - Baseline Category Placebo BID (n=20)
Slide 27: AXA1125 responders had significant improvements in 6MWT
© 2022 Axcella Therapeutics. All rights reserved. 27 AXA1125 responders had statistically significant improvements and were able to walk farther This effect only seen in subjects who received AXA1125 Change in Ratio (Observed/Predicted) 6MWT (%) Spearman Correlation Coefficient (p - value) AXA1125 3
Slide 28: No Change in Phosphocreatine recovery rate time constant
© 2022 Axcella Therapeutics. All rights reserved. 28 PCR t , phosphocreatine recovery rate time constant. Rousell et al Biochimica Biophysica Acta 2000 No Change in Phosphocreatine recovery rate time constant ( PCr t ) Much greater than expected variation in baseline – makes PCr t not useful as a cl
Slide 29: Trend Toward Improving Lactate Levels
© 2022 Axcella Therapeutics. All rights reserved. 29 AUC, area under the curve. AXA1125 Patients Showed A Trend Toward Improving Lactate Levels • Baseline assumption that peak lactate would be high (> 3 mMol /L) • Trend toward difference in model estimated mean (LSM) when accounting for difference i
Slide 30: AXA1125 was safe and well tolerated
© 2022 Axcella Therapeutics. All rights reserved. 30 . TEAE, treatment emergent adverse events. AXA1125 was safe and well tolerated in this study TEAE s (Treatment Emergent Adverse Events) Placebo (n=20) AXA1125 (n=21) Subjects with at least one TEAE 4 (20.0%) 11 (52.4%) Subjects with at least one s
Slide 31: Conclusion
© 2022 Axcella Therapeutics. All rights reserved. 31 CFQ - 11, Chalder Fatigue Questionnaire 11 item scale; PCr t , phosphocreatine recovery rate time constant Conclusion • AXA1125, compared to placebo, resulted in: – Statistically significant improvements in fatigue as measured by CFQ - 11 – Improv
Slide 32: Long COVID: Patient Journey
• “I have lost everything – my job, my life, my partner. Most of all I have lost myself. I want the old me back.” – P.L Long COVID: Patient Journey Source:https :// www.youtube.com / watch?v =IIeOoS_A4c8 Long COVID SOS support
Slide 33: Mechanism of Disease & AXA1125
© 2022 Axcella Therapeutics. All rights reserved. NASDAQ: AXLA 2 August, 2022 Mechanism of Disease & AXA1125 Karim Azer , PhD VP, Head of Platform & Discovery
Slide 34: COVID Hijacks Mitochondrial Metabolism and Leads to Chronic Inflammation
© 2022 Axcella Therapeutics. All rights reserved. 34 COVID - 19 Hijacks Mitochondrial Metabolism, Dysregulates Vascular System and Leads to Chronic Inflammation in Long Covid Building on a Foundation of AXA1125 Multi - Targeted Activity • Vascular environment dysfunction, pro - inflammatory state, a
Slide 35: AXA1125 Targets Key Environment, Inflammation and Metabolism Biologies
© 2022 Axcella Therapeutics. All rights reserved. 35 AXA1125 Targets Key Environment, Inflammation and Metabolism Biologies in Long Covid Key Hypotheses for Multi - Targeted Effect of AXA1125 Use in Long COVID • AXA1125 multi - targeted MOA is proposed to improve vascular environment, inflammation,
Slide 36: Key MOA Takeaways from AXA1125 in Long Covid Fatigue
© 2022 Axcella Therapeutics. All rights reserved. 36 Key MOA Takeaways from AXA1125 in Long Covid Fatigue Disease MOA Biological Impact Improved Clinical Treatment Response Biomarker(s) in LC MOA Concordance from NASH Studies Preliminary evidence in Pre - clinical Models Vascular Environment Dysfunc
Slide 37: AXA1125 Multi-Targeted MOA Restores Key Biologies
© 2022 Axcella Therapeutics. All rights reserved. 37 AXA1125 Multi - Targeted MOA Restores Key Biologies Implicated in LC Fatigue Patients • Vascular environment dysfunction, inflammation and suppressed metabolism are implicated in LC patients and reported in clinical registries – suppressed mitocho
Slide 38: Long COVID Fatigue: Background and Trial Discussion
Long COVID Fatigue: Background and Trial Discussion Jason H Maley, MD, MS Assistant Professor of Medicine , Harvard Medical School Director, Critical Illness and COVID - 19 Survivorship Program Co - Chair , American Academy of PM&R Long COVID Clinic Collaborative Co - Investigator , NIH Researching
Slide 39: Conflicts of Interest
Conflicts of Interest I was not involved in the design, conduct, or reporting of this Phase 2a clinical trial. Following this trial, I began work as a scientific advisor on the topic of long COVID for Axcella .
Slide 40: - year - old man, engineer, triathlete, COVID - in December 2020 • Initial
38 - year - old man, engineer, triathlete, COVID - 19 in December 2020 • Initial illness managed at home, felt it was a “mild cold,” did not require hospitalization and symptoms resolved by day 4 of illness • 8 weeks later: severe physical and mental exhaustion after an average day of work, had to s
Slide 41: - year - old man, engineer, triathlete, COVID - in December 2020 • Initial
38 - year - old man, engineer, triathlete, COVID - 19 in December 2020 • Initial illness managed at home, felt it was a “mild cold,” did not require hospitalization and symptoms resolved by day 4 of illness • 8 weeks later: severe physical and mental exhaustion after an average day of work, had to s
Slide 42: • - month wait list , over 1000 patients seen at our clinic, same
• 6 - 8 month wait list , over 1000 patients seen at our clinic, same or longer wait around the country at 100+ long COVID clinics • No existing physical or cognitive fatigue treatments targeting biology of long COVID • Continue to see new patients with severe long COVID symptoms who were infected i
Slide 43: • Measure progress in small steps every - months , with many patients experiencing
• Measure progress in small steps every 4 - 6 months , with many patients experiencing ongoing symptoms 2+ years from infection • Recovery from prolonged, severe fatigue in 1 month is exceptional , not seen in the setting of our clinics • Anticipate ongoing pressing need for treatment indefinitely –
Slide 44: Characterizing Long COVID Fatigue
Impaired oxygen extraction during exercise Characterizing Long COVID Fatigue Prolonged post - infectious inflammation Immune Dysregulation Exhaustion after minimal physical activity Non - restorative sleep Post - exertional malaise Impairs function at work and home Accompanying cognitive impairment
Slide 45: Characterizing Long COVID Fatigue
Impaired oxygen extraction during exercise Prolonged post - infectious inflammation Immune Dysregulation Exhaustion after minimal physical activity Non - restorative sleep Post - exertional malaise Impairs function at work and home Accompanying cognitive impairment EMERGING EVIDENCE CLINICAL CHARACT
Slide 46: My Key Takeaways from Trial
My Key Takeaways from Trial • Patient - reported outcome – Chalder Fatigue Scale ( CFQ - 11) – is the outcome that matters to patients and clinicians • Clinically significant improvement in physical and cognitive domains • Physical performance (6MWT) improved among those responsive to treatment
Slide 47: What would this mean to patients and to me
What would this mean to patients and to me • First fatigue therapy addressing underlying biology – no current treatment for fatigue • Cannot overstate urgency for treatments among patients and clinicians • Ability to return to work , maintain income, participate in home life • Return of cognitive fu
Slide 48: Phase 2A Long COVID Study Results Presentation
© 2022 Axcella Therapeutics. All rights reserved. NASDAQ: AXLA Axcella Therapeutics Phase 2A Long COVID Study Results Presentation Bill Hinshaw , President and CEO, Axcella August 2022
Slide 49: Milestone Rich Time
© 2022 Axcella Therapeutics. All rights reserved. 49 Milestone timing based on current expectations and subject to change. * Assumes positive Phase 2a data readout. Milestone Rich Time Program Update Timing AXA1125 for Long COVID Phase 2a Enrollment Completion Q2 2022 x Phase 2a Top - Line Data Q3 2
Slide 50: In Summary
© 2022 Axcella Therapeutics. All rights reserved. 50 Milestone timing based on current expectations and subject to change. * Assumes positive Phase 2a data readout. In Summary • AXA1125 Demonstrated Highly Statistically Significant and Clinically Relevant Results • COVID infections are continuing •
Slide 51: Q&A
*** Confidential *** © 2022 Axcella Therapeutics. All rights reserved. Q&A Dr. Jason Maley Beth Israel Deaconess Medical Center Dr. Betty Raman Radcliffe Department of Medicine, Oxford University Bob Crane Chief Financial Officer, Axcella Dr. Margaret Koziel Chief Medical Officer, Axcella Bill Hinsh
Axcella Health — Technical Presentation (August 2022) on 6ix